Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Monopar Therapeutics Inc.NASDAQ: MNPR
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 472.4% from a year ago
Short-term investments stood at $84.95M at the end of Q1 FY2026, up 472.4% from a year earlier and up 8.1% from the prior quarter. Over 3 fiscal years it compounded at +151.6% a year.
Context
- Short-term investments amounted to 61.6% of total assets at the end of Q1 FY2026, up 34.6 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +472.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 78.57M USD
- Year-over-year change
- +445.7%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78.57M | +445.7% |
| FY2024 | 2024-12-31 | 14.4M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 4.93M | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +472.4% is the 2nd highest of 7, against a peer median of +21.5%.
- Short-term investments amounts to 61.6% of total assets for MNPR, versus a peer median of 25.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $411.79M USD | +3.1% | -4.6% | 56.8% | |
| Sep 2026 | $248.74M USD | — | — | 49.2% | |
| Mar 2026 | $139.52M USD | +94.9% | +5.5% | 68.0% | |
| Mar 2026 | $108.04M USD | +39.9% | -49.2% | 60.6% | |
| Mar 2026 | $87.71M USD | +923.4% | +42.9% | 40.3% | |
| Mar 2026 | $84.95M USD | +472.4% | +151.6% | 61.6% | |
| Dec 2025 | €6.22M EUR | -56.8% | -28.9% | 9.9% | |
| Sep 2026 | $0 USD | -100.0% | +27.1% | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MNPR) | — | +21.5% | +0.5% | 25.1% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.